/content/dam/asset-migration/headshots/uk-doctor-headshots/UK_oncology_Tathagata Das v2.jpg

Dr Tathagata  Das

Dr Tathagata  Das
MBBS, MD (Radiation Oncology), MRCP, FRCR, Consultant Clinical Oncologist

Languages spoken


Expert in

Lung cancer, Genitourinary cancer and Skin cancer


Dr Das has been working as Consultant, Clinical Oncology in Weston Park Hospital, Sheffield, since November 2013. He is one of the 35 Oncology Consultants providing world class cancer care to a population of 1.8 million in the South Yorkshire and North Derbyshire region.

Dr Das specialises in the treatment of Lung Cancer and Non-melanoma skin cancers. Till January 2017, he was also treating Urological Malignancies.

He is involved with the development of Stereotactic Ablative Body Radiotherapy (SABR) services in Weston Park Hospital, and is currently the Chair of the SABR MDT at Weston Park Hospital and the MDT discusses the suitability for SABR of all patients referred from the South Yorkshire and North Derbyshire region.

Dr Das is the Lung Cancer group Lead in the trust and has been actively involved in the development of the Lung Cancer services in the trust. As the Lung group lead, he is responsible for various management responsibilities like chairing the Lung Research group meeting once every quarter; making applications to the Drugs and Therapeautic committee for approval of new drugs; ensuring that the Lung treatment protocols are reviewed and up to date; Audit our prescribing practice to ensure that we comply with the standards laid out via NICE Technical Appraisals.

Dr Das is the Audit Lead for the Oncology Directorate and in this capacity ensure that National and Local Clinical Audits and Service Improvement projects are conducted and completed in a timely manner.

He has been the Oncology Undergraduate Lead for the Sheffield Teaching Hospitals Trust and he manages the Oncology attachments of the Undergraduate medical Students of Sheffield University. 

As a consultant, Dr Das is actively involved in the training of doctors. He is the Clinical and Educational supervisor for junior doctors in Foundation year and Specialist Registrar Training.

Dr Das has recently been involved in developing the service of Ultrasound guided fiducial marker insertion in Prostate cancer patients. he was involved in the procurement of the Ultrasound scanner through Weston Park cancer Charity funding and then went to Clatterbridge Cancer Centre to learn fiducial marker insertion.

Dr Das has been actively involved in teaching undergraduate Medical Students and registrars (he teaches the FRCR part 1 course in Leeds and the FRCR part 2 course run in Weston Park Hospital.

Dr Das has been a Royal College of Radiologist Tutor (since July 2018) for the trust and has played an active role in ensuring that the specialty trainees have the best possible training in the trust and make sure that the training is of a high standard.

Career positions

Current position(s)
  • Consultant Clinical Oncologist, Nottingham

Clinical interests

  • Lung cancer and mesothelioma
  • Non-melanoma skin cancers
  • Urological Malignancies
  • SABR, IMRT, and IGRT

Publications & affiliations

  1. Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres. Clin Oncol (R Coll Radiol). 2018 Mar; 30(3):144-150. doi: 10.1016/j.clon.2017.12.019. Epub 2018 Jan 12
  2. 111O Impact of cardiac doses on survival of non-small cell lung cancer (NSCLC) patients following radical accelerated radiotherapy (Apr 2018)Journal of Thoracic Oncology
  3. Outcomes of patients in the North Trent region with advanced with advanced non-small cell lung cancer treated with maintenance Pemetrexed following induction with platinum non-pemetrexed doublet chemotherapy; (Lung Cancer, vol.103;January 2017; pp S31-S31)
  4. Testing for EGFR Mutations in Non Small Cell Lung Cancer: A population based Analysis in North Trent; (Lung Cancer; Vol 71, January 2011; p.S13)
  5. Systemic therapy in the Elderly: a network Audit of Non Small Cell Lung Cancer Patients; (Lung Cancer; Vol 75, January 2012; p.S10)